Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
 
Via Benzinga
(BLUE) - Analyzing bluebird bio's Short Interest
 
Via Benzinga
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
bluebird bio Stock Signals Potential to be a Multi-bagger
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do 
Via MarketBeat
Topics Economy
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
bluebird bio stock is ripe for a 400% institutional short squeeze
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in 
Via MarketBeat
Topics Economy
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence. 
Via The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
From bluebird bio, Inc.
Via Business Wire
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Should You Invest in Bluebird Bio Right Now?
After two December share price crashes, there's no evident cure for Bluebird Bio's ills. 
Via The Motley Fool
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
Can things get better for this struggling stock? 
Via The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
Doing a little math and doing a little extra research can make a big difference. 
Via The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however,... 
Via Benzinga
Topics Stocks
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.